Why Gilead Sciences Is a Must-Own Stock

Source: Thinkstock

Source: Thinkstock

Gilead Sciences Inc. (NASDAQ:GILD) is one of my top choices for any stocks moving forward through 2014 into 2015. This company is a behemoth of a biopharmaceutical company. It designs, discovers, develops, and commercializes medicines for the treatment of a number of different life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company’s flagship products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults. It also has Sovaldi, Viread, and Hepsera products for the treatment of liver disease.

Further, it offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension and Ranexa for the treatment of chronic angina. Another popular product is Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. Although it also sells a number of other medications, it also has exciting product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. Not only does it have current and potential future blockbusters in its pipeline, the company is also making a killing.

Just how much is the company hauling in? Well, in its most recent quarter, total revenues increased to $5.00 billion from $2.53 billion for the first-quarter of 2013. Product sales increased to $4.87 billion for the first-quarter of 2014 compared to $2.39 billion for the first-quarter of 2013. Net income for the first-quarter of 2014 was $2.23 billion, or $1.33 per diluted share compared to $722.2 million, or $0.43 per diluted share for the first-quarter of 2013. Wow. The non-GAAP net income, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $2.49 billion, or $1.48 per diluted share compared to $801.9 million, or $0.48 per diluted sharelast year.